Sermorelin (5mg)

Sermorelin — Growth Hormone–Releasing Hormone (GHRH) Analog

Sermorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH 1-29). It has been studied for its ability to stimulate the pituitary gland’s natural release of growth hormone (GH), making it of interest in research involving the GH/IGF-1 axis, endocrine signaling, metabolism, and body composition.

Potential Areas of Research Interest:

• Growth Hormone Release — Stimulates the pituitary gland to increase endogenous growth hormone secretion.

• GH/IGF-1 Signaling — Studied for its influence on growth hormone and downstream IGF-1 pathways.

• Body Composition — Research involving the GH axis has examined relationships with lean body mass and fat metabolism.

• Recovery & Tissue Maintenance — Growth hormone signaling plays an important role in tissue growth, repair, and maintenance.

• Metabolic Function — Of research interest for GH-related effects on lipid, glucose, and energy metabolism.

• Sleep & GH Secretion — Growth hormone secretion naturally follows a pulsatile pattern and is strongly associated with sleep, making GHRH signaling an area of interest in sleep and endocrine research.

Sermorelin has a different regulatory history from many research peptides: an FDA-approved sermorelin product was previously marketed in the United States but was later discontinued. Current compounded or research products should not be represented as FDA-approved simply because sermorelin was previously marketed as an approved drug.

FOR RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION.